- Home
- EQX vs ARWR Comparison
EQX vs ARWR Comparison
Compare EQX & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- ARWR
- Stock Information
- Founded
- EQX 2007
- ARWR 2003
- Country
- EQX Canada
- ARWR United States
- Employees
- EQX N/A
- ARWR N/A
- Industry
- EQX Precious Metals
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- ARWR Health Care
- Exchange
- EQX Nasdaq
- ARWR Nasdaq
- Market Cap
- EQX 2.7B
- ARWR 2.5B
- IPO Year
- EQX N/A
- ARWR 1993
- Fundamental
- Price
- EQX $5.71
- ARWR $18.54
- Analyst Decision
- EQX
- ARWR Buy
- Analyst Count
- EQX 0
- ARWR 11
- Target Price
- EQX N/A
- ARWR $45.33
- AVG Volume (30 Days)
- EQX 3.9M
- ARWR 1.1M
- Earning Date
- EQX 11-06-2024
- ARWR 11-26-2024
- Dividend Yield
- EQX N/A
- ARWR N/A
- EPS Growth
- EQX 302.88
- ARWR N/A
- EPS
- EQX 0.60
- ARWR N/A
- Revenue
- EQX $1,236,929,000.00
- ARWR $19,648,000.00
- Revenue This Year
- EQX $46.67
- ARWR N/A
- Revenue Next Year
- EQX $55.51
- ARWR $100.95
- P/E Ratio
- EQX $10.62
- ARWR N/A
- Revenue Growth
- EQX 17.84
- ARWR N/A
- 52 Week Low
- EQX $3.95
- ARWR $17.05
- 52 Week High
- EQX $6.50
- ARWR $39.83
- Technical
- Relative Strength Index (RSI)
- EQX 54.14
- ARWR 38.58
- Support Level
- EQX $5.07
- ARWR $18.03
- Resistance Level
- EQX $5.83
- ARWR $22.03
- Average True Range (ATR)
- EQX 0.22
- ARWR 0.87
- MACD
- EQX 0.05
- ARWR -0.30
- Stochastic Oscillator
- EQX 85.80
- ARWR 11.38
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing pipeline of growth projects.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.